Proven protection. Extra purification.

An extra-purified
IVIG

A longstanding goal within the immunoglobulin (IG) industry has been to remove activated coagulation factor XI (FXIa), a plasma-based protein linked to IVIG-related thromboembolic events.1

ALYGLO is manufactured with G-XI™ Technology, which utilizes cation exchange (CEX) chromatography under special conditions that are proven to reduce FXIa to undetectable limits.1

An effective IVIG

In a clinical study of 33 patients with primary immunodeficiency (PI), ALYGLO demonstrated proven efficacy, safety, and tolerability, with only 0.03 acute serious bacterial infection (ASBI) per patient year and reduced impact on daily living.2,a

Upper one-sided 99% confidence limit was 0.31, which met the predefined success rate of <1 ASBI per patient year (intent-to-treat [ITT] population).2

It’s time to get
started

See what patients might be right for ALYGLO and learn about dosing and administration.

Support throughout
the journey

Learn how ALYGLO ASSIST can help you and your patients navigate getting started and managing costs.

Also find resources to download for your office and for your patients.

As a global manufacturer of plasma therapeutics, we have been delivering safe and effective therapies to patients for more than 50 years.

Our mission is to accelerate the development and delivery of therapies for patients in need of treatment.

We are also working to help address challenges associated with intravenous immunoglobulin (IVIG).

Learn how we can help
cover the cost of ALYGLO

aStudy design: Efficacy, safety, and tolerability of ALYGLO were evaluated in a prospective, open-label study of 33 adults aged 17-70 years. See the full clinical study design.

References:

  1. Kang GB, Huber A, Lee J, et al. Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation. Front Cardiovasc Med. 2023;10:1253177.
  2. ALYGLO Prescribing Information. GC Biopharma; 2023.
+
INDICATION

ALYGLO® is indicated for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE

  • Thrombosis may occur with immune globulin intravenous (IGIV) products, including ALYGLO. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.

  • Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients.

  • Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ALYGLO does not contain sucrose.

  • For patients at risk of thrombosis, renal dysfunction or renal failure, administer ALYGLO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

  • Contraindications: ALYGLO is contraindicated in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.
  • Hypersensitivity: In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. Epinephrine should be available for immediate treatment of severe acute hypersensitivity reactions.
  • Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur.
  • Aseptic Meningitis Syndrome (AMS): Aseptic meningitis syndrome (AMS) may occur, especially with high doses or rapid infusion. AMS usually begins within several hours to 2 days following ALYGLO treatment. Discontinuation of treatment has resulted in remission of AMS within several days without sequelae.
  • Hemolysis: Delayed hemolytic anemia due to enhanced red blood cell (RBC) sequestration and acute hemolysis consistent with intravascular hemolysis have been reported. Cases of severe hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have occurred following infusion of IGIV. Closely monitor patients for clinical signs and symptoms of hemolysis, particularly patients with risk factors.
  • Transfusion-Related Acute Lung Injury: Noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) may occur. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Patients with TRALI may be managed using oxygen therapy with adequate ventilator support. Monitor patients for pulmonary adverse reactions.
  • Transmissible Infectious Agents: Because ALYGLO is made from human blood, it may carry a risk of transmitting infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent).
  • Interference with Laboratory Tests: After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for a misleading interpretation.
  • Adverse reactions (observed in ≥ 5% of study subjects) were headache, nausea/vomiting, fatigue, nasal/sinus congestion, rash, arthralgia, diarrhea, muscle pain/aches, infusion site pain/swelling, abdominal pain/discomfort, cough, and dizziness.
  • It is recommended that ALYGLO be administered separately from other drugs or medications.

For more information about ALYGLO, please see full Prescribing Information.

Site map Contact us Privacy statement Cookie preferences Terms of use

You are encouraged to report negative side effects of prescription drugs to the FDA. If you would like to speak to a Medical Affairs representative, have an inquiry related to drug safety, or to report adverse events, please contact 1-833-426-6426, or email medicalinfo@gcbiopharmausa.com, or e-fax 1-866-728-7855, or visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Annual declaration of compliance from the state of California

©2025 GC Biopharma USA, Inc. All rights reserved.
All trademarks are the property of their respective owners.
ALY‌-‌C‌-‌0024  7/2025